Tower Research Capital LLC TRC Increases Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Tower Research Capital LLC TRC raised its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 368.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,350 shares of the biotechnology company’s stock after acquiring an additional 2,635 shares during the period. Tower Research Capital LLC TRC’s holdings in Aurinia Pharmaceuticals were worth $30,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kingswood Wealth Advisors LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $248,000. Union Bancaire Privee UBP SA acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $108,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Aurinia Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 2,857 shares during the period. Blue Trust Inc. increased its stake in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares in the last quarter. Finally, Atria Wealth Solutions Inc. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $135,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Up 3.8%

Shares of NASDAQ AUPH opened at $8.15 on Friday. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -54.33 and a beta of 1.16. Aurinia Pharmaceuticals Inc. has a 12-month low of $5.11 and a 12-month high of $10.67. The stock’s 50 day simple moving average is $8.02 and its 200 day simple moving average is $8.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.08. The firm had revenue of $62.47 million for the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. Equities research analysts expect that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 27th.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the sale, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at approximately $15,631,136. This trade represents a 9.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Greg Keenan sold 8,305 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the transaction, the insider now directly owns 153,484 shares in the company, valued at approximately $1,263,173.32. This trade represents a 5.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 343,898 shares of company stock worth $2,753,094 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.